Condition (MeSH)
Femoral Neuropathy
ClinicalTrials.gov lists 17 trials for Femoral Neuropathy or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
17 of the 17 trials are tagged with Femoral Neuropathy itself; the rest are tagged with a narrower condition beneath it.
When did Femoral Neuropathy trials start? (11)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 3
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2024 | 3 |
| 2023 | 2 |
| 2022 | 1 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 1 |
| 2015 | 1 |
| 2014 | 1 |
| 2011 | 1 |
Showing 10 of 11 earlier years.
No forecast is made for this condition: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Femoral Neuropathy trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 3 | 1 |
| Not applicable | 15 |
| Observational | 1 |
How many Femoral Neuropathy trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Enrolling by invitation | 1 |
| Completed | 13 |
| Withdrawn | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Femoral Neuropathy trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Istanbul Training and Research Hospital | 1 |
| Mersin Training and Research Hospital | 1 |
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Low Level Laser Therapy | 1 |
| NaCl 0.9% NS | 1 |
| Steroid (dexamethasone) Injection | 1 |
| Nerve Injection - Ultrasound | 1 |
| Nerve Injection- Nerve Stimulator | 1 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Femoral Neuropathy? (15)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Unusual causes for meralgia paresthetica: systematic review of the literature and single center experience. | Neurosurgical review | 2023 | Yes |
| Meralgia Paresthetica: Relevance, Diagnosis, and Treatment. | Deutsches Arzteblatt international | 2023 | Yes |
| Treatment of meralgia paresthetica (Lateral Femoral Cutaneous Neuropathy): A meta-analysis of ultrasound-guided injection versus surgery. | European journal of radiology | 2021 | Yes |
| Lateral Femoral Cutaneous Nerve Radiofrequency Ablation for Long-term Control of Refractory Meralgia Paresthetica. | Pain medicine (Malden, Mass.) | 2020 | Yes |
| Meralgia Paresthetica After Spine Surgery on the Jackson Table. | Clinical spine surgery | 2018 | Yes |
Showing 5 of 15 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.